Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
1.950
0.00 (0.00%)
Dec 20, 2024, 4:00 PM EST - Market closed
Climb Bio Statistics
Total Valuation
Climb Bio has a market cap or net worth of $131.09 million. The enterprise value is -$86.78 million.
Market Cap | 131.09M |
Enterprise Value | -86.78M |
Important Dates
The last earnings date was Tuesday, November 12, 2024, after market close.
Earnings Date | Nov 12, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Climb Bio has 67.22 million shares outstanding. The number of shares has increased by 43.11% in one year.
Current Share Class | 67.22M |
Shares Outstanding | 67.22M |
Shares Change (YoY) | +43.11% |
Shares Change (QoQ) | +120.81% |
Owned by Insiders (%) | 0.73% |
Owned by Institutions (%) | 39.85% |
Float | 30.30M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.60 |
P/TBV Ratio | 0.60 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 57.73, with a Debt / Equity ratio of 0.00.
Current Ratio | 57.73 |
Quick Ratio | 56.78 |
Debt / Equity | 0.00 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -42.08% and return on invested capital (ROIC) is -7.27%.
Return on Equity (ROE) | -42.08% |
Return on Assets (ROA) | -7.15% |
Return on Capital (ROIC) | -7.27% |
Revenue Per Employee | n/a |
Profits Per Employee | -$6.28M |
Employee Count | 11 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
Beta (5Y) | -0.40 |
52-Week Price Change | n/a |
50-Day Moving Average | 3.57 |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | 21.12 |
Average Volume (20 Days) | 264,101 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -19.15M |
Pretax Income | n/a |
Net Income | -69.12M |
EBITDA | n/a |
EBIT | -19.15M |
Earnings Per Share (EPS) | -$1.81 |
Balance Sheet
The company has $193.35 million in cash and $58,000 in debt, giving a net cash position of $217.87 million or $3.24 per share.
Cash & Cash Equivalents | 193.35M |
Total Debt | 58,000 |
Net Cash | 217.87M |
Net Cash Per Share | $3.24 |
Equity (Book Value) | 218.78M |
Book Value Per Share | 3.25 |
Working Capital | 194.19M |
Cash Flow
Operating Cash Flow | -10.99M |
Capital Expenditures | n/a |
Free Cash Flow | -10.99M |
FCF Per Share | -$0.16 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Climb Bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -43.11% |
Shareholder Yield | -43.11% |
Earnings Yield | -52.73% |
FCF Yield | -8.38% |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 2 |